Patents by Inventor Yu-Kyoung Oh
Yu-Kyoung Oh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230000984Abstract: The present invention relates to a biocompatible photothermal composition that can be used in various fields including the treatment of cancer and skin diseases.Type: ApplicationFiled: August 22, 2022Publication date: January 5, 2023Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Yu-Kyoung OH, Seungbeom Ko
-
Publication number: 20200384110Abstract: The present invention relates to a biocompatible photothermal composition that can be used in various fields including the treatment of cancer and skin diseases.Type: ApplicationFiled: January 2, 2018Publication date: December 10, 2020Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Yu-Kyoung OH, Seungbeom KO
-
Patent number: 10172943Abstract: Provided is an irinotecan-loaded dual-reverse thermosensitive formulation, which is a dual-reverse thermosensitive hydrogel composition including nanoparticles including irinotecan and lipids; a hydrogel; and a stabilizer.Type: GrantFiled: January 21, 2016Date of Patent: January 8, 2019Assignee: INDUSTRY—UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUSInventors: Han-Gon Choi, Fakhar Ud Din, Dong Wuk Kim, Dong Shik Kim, Chul Soon Yong, Jong Oh Kim, Yu-Kyoung Oh
-
Publication number: 20180147282Abstract: Provided is an irinotecan-loaded dual-reverse thermosensitive formulation, which is a dual-reverse thermosensitive hydrogel composition including nanoparticles including irinotecan and lipids; a hydrogel; and a stabilizer.Type: ApplicationFiled: January 21, 2016Publication date: May 31, 2018Inventors: Han-Gon CHOI, Fakhar UD DIN, Dong Wuk KIM, Dong Shik KIM, Chul Soon YONG, Jong Oh KIM, Yu-Kyoung OH
-
Patent number: 9555091Abstract: The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., HPV L1), enabling to function as a more efficient DNA vaccine.Type: GrantFiled: July 30, 2014Date of Patent: January 31, 2017Assignees: KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP., KR BIOTECH CO., LTD.Inventors: Young-Bong Kim, Hee Jung Lee, Nuri Park, Yu-Kyoung Oh
-
Patent number: 9217149Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.Type: GrantFiled: September 3, 2014Date of Patent: December 22, 2015Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Eun Young Song, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung
-
Publication number: 20150030621Abstract: The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., HPV L1), enabling to function as a more efficient DNA vaccine.Type: ApplicationFiled: July 30, 2014Publication date: January 29, 2015Inventors: Young-Bong KIM, Hee Jung Lee, Nuri Park, Yu-Kyoung Oh
-
Publication number: 20140371300Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.Type: ApplicationFiled: September 3, 2014Publication date: December 18, 2014Inventors: Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Eun Young Song, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung
-
Patent number: 8846630Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.Type: GrantFiled: November 1, 2010Date of Patent: September 30, 2014Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung, Seok Hoon Song
-
Patent number: 8431543Abstract: The present invention relates to a conjugate of chitosan and polyamine polymer that is useful for transferring a desired gene medicine into cells, and a method for preparing the same. In particular, the present invention relates to a double conjugate that is prepared by 1 in king poly-L-arginine to low molecular weight chitosan or triple conjugate that is prepared by additionally linking polyethylene glycol (PEG) to the double conjugate, and a method for preparing the same. The chitosan based cationic polymer conjugate of the present invention forms a complex with negatively charged gene medicine such as plasmid DNA and small interfering RNA to efficiently transfer the desired gene medicine into cells with low cytotoxicity. Accordingly, the conjugate can be used as an effective delivery system for in vivo administration of gene medicine.Type: GrantFiled: January 7, 2008Date of Patent: April 30, 2013Assignee: Engene, IncInventors: Myung-Ok Park, Yu-Kyoung Oh, Sang Myoung Noh, Sung Sik Bang, Myung Suk Kim
-
Patent number: 8377899Abstract: The present invention relates to a composition for the treatment of cervix cancer, more precisely a composition for the treatment of cervix cancer comprising the first active part containing human papilloma virus (referred as “HPV” hereinafter) specific siRNA as an active ingredient and the second active part containing an anticancer agent as an active ingredient. The composition for the treatment of cancer of the present invention has better anticancer effect than the single therapy of the HPV specific siRNA or the anticancer agent, and has an advantage of reducing side effects by using the anticancer agent at a low concentration.Type: GrantFiled: November 5, 2007Date of Patent: February 19, 2013Assignee: SNU R&DB FoundationInventors: Young Kee Shin, Hun Soon Jung, Yu Kyoung Oh
-
Publication number: 20130028957Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.Type: ApplicationFiled: November 1, 2010Publication date: January 31, 2013Inventors: Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung, Seok Hoon Song
-
Patent number: 8318856Abstract: The present invention relates to a delivery system for nucleic acid using a cationic polymer conjugate, and more specifically relates to a delivery system for nucleic acid comprising a cationic polymer conjugate prepared by conjugating hyaluronic acid or its derivative and polyethyleneimine, and a composition of delivering a nucleic acid into mammalian cell comprising a complex of the nucleic acid and a cationic polymer conjugate with electrostatic binding.Type: GrantFiled: April 4, 2008Date of Patent: November 27, 2012Assignees: Postech Academy-Industry Foundation, Korea University Industry and Academy Collaboration FoundationInventors: Yu-Kyoung Oh, Hyun-Gu Kang, Ji-Seok Kim, Jiang Ge, Ki-Su Kim, Ki-Tae Park, Su-Eun Han, Ga-Yong Shim, Ii-Hwan Cho, Sei-Kwang Hahn
-
Publication number: 20120258038Abstract: The present invention relates to a composition for preventing, treating or theranosis of apoptosis-related diseases comprising liposome comprising apoptotic cell-targeting peptides, label substances and a therapeutic agent. The present invention may be used for drug delivery to the apoptotic cells in cancer or tumor mass, the apoptotic myocardial cells in myocardial infarction lesion, the apoptotic stroke cells in stroke lesion, the apoptotic cells in arteriosclerosis lesion and further may be used for detection of the cells and imaging diagnosis. Therefore, it can be used for theranosis as well as preventing or treating the diseases.Type: ApplicationFiled: May 11, 2012Publication date: October 11, 2012Applicant: Kyungpook National University Industry-Academic Cooperation FoundationInventors: Byung-Heon Lee, In San Kim, Yu Kyoung Oh
-
Publication number: 20120021044Abstract: The present invention provides a novel cationic lipid, a preparation method of the same and a delivery system comprising the same. The cationic lipid of the present invention is used for the preparation of delivery systems of nucleic acids or physiologically active anionic proteins. The cationic lipid of the present invention can be conveniently prepared and purified by a simple process and is therefore economically highly advantageous for industrial-scale production thereof. Further, a nucleic acid or protein delivery system comprising the cationic lipid of the present invention not only significantly improves the intracellular delivery efficiency of desired nucleic acid drugs (such as DNAs, RNAs, siRNAs, antisense oligonucleotides, and nucleic acid aptamers) or anionic proteins having physiological activity, but also is usefully used to augment therapeutic efficacy of nucleic acid or protein drugs due to attenuated cytotoxicity of the delivery system.Type: ApplicationFiled: August 20, 2008Publication date: January 26, 2012Applicants: SNU R&DB FOUNDATION, KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATIONInventors: Yu-Kyoung Oh, Min-Sung Suh, Hye-Jeong Shin, Ga Yong Shim
-
Publication number: 20110160282Abstract: The present invention provides at least one siRNA (small interfering RNA) which inhibits the expression of Mcl-1 within the cell, and which is selected from siRNA having SEQ. ID. NO. 1 sense sequence and SEQ. ID. NO. 2 antisense sequence, siRNA having SEQ. ID. NO. 3 sense sequence and SEQ. ID. NO. 4 antisense sequence, and siRNA having SEQ. ID. NO. 5 sense sequence and SEQ. ID. NO. 6 antisense sequence. The invention also provides a nucleic-acid pharmaceutical composition for cancer therapy comprising the same. The siRNA of the present invention kills cancer cells by inhibiting the expression of Mcl-1 which is commonly expressed in cancer cells by means of RNA-mediated interference (RNAi), and the composition of the present invention can be used as an outstanding anti-cancer preparation.Type: ApplicationFiled: February 18, 2009Publication date: June 30, 2011Applicants: Korea University Research and Business Foundation, SNU R&DB FoundationInventors: Yu-Kyoung Oh, Gayong Shim, Sang-Hee Kim
-
Publication number: 20100285056Abstract: The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., HPV L1), enabling to function as a more efficient DNA vaccine.Type: ApplicationFiled: January 9, 2009Publication date: November 11, 2010Applicants: Konkuk University Industrial Cooperation Corp., KR Biotech Co., Ltd.Inventors: Young-Bong Kim, Hee Jung Lee, Nuri Park, Yu-Kyoung Oh
-
Publication number: 20100203112Abstract: The present invention provides a cationic phospholipid liposome composition comprising 1,2-dioleoyl-sn-glycero-S-ethylphosphocholine (EDOPC), 3?-[N—(N?,N?-dimethylaminoethane)-carbamoyl] cholesterol (DC-cholesterol) and 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPhPE), a liposome-nucleic acid complex which is capable of forming a complex therewith, and a pharmaceutical composition comprising the same. The cationic phospholipid liposome of the present invention is highly effective for intracellular delivery of nucleic acids and reduction of cytotoxicity, as compared to conventional liposome products. Therefore, the present invention can be useful for gene therapy via intracellular delivery of a desired material to target cells.Type: ApplicationFiled: March 28, 2008Publication date: August 12, 2010Applicant: SNU R&DB FOUNDATIONInventors: Yu-Kyoung Oh, Hye-Jeong Shin, Min-Sung Suh, Ga Yong Shim
-
Patent number: 7745419Abstract: The present invention provides a small interfering RNA (siRNA) that is capable of inhibiting intracellular expression of Wnt1 through complementary binding to a Wnt1 transcript (mRNA transcript) base sequence and a pharmaceutical composition for treating cancer comprising the same. siRNA of the present invention which is complementary to a base sequence of a Wnt1 transcript (mRNA) provides apoptotic cancer cell death due to inhibition of expression of Wnt1 commonly expressed in cancer cells, by RNA-mediated interference (RNAi). Therefore, the composition of the present invention comprising the same can be used as an excellent anticancer drug.Type: GrantFiled: September 19, 2008Date of Patent: June 29, 2010Assignee: Korea University Industrial & Academic Collaboration FoundationInventors: Yu-Kyoung Oh, Ga Yong Shim, Sang-Hee Kim
-
Publication number: 20100144035Abstract: The present invention relates to a delivery system for nucleic acid using a cationic polymer conjugate, and more specifically relates to a delivery system for nucleic acid comprising a cationic polymer conjugate prepared by conjugating hyaluronic acid or its derivative and polyethyleneimine, and a composition of delivering a nucleic acid into mammalian cell comprising a complex of the nucleic acid and a cationic polymer conjugate with electrostatic binding.Type: ApplicationFiled: April 4, 2008Publication date: June 10, 2010Inventors: Yu-Kyoung Oh, Hyun-Gu Kang, Ji-Seok Kim, Jiang Ge, Ki-Su Kim, Ki-Tae Park, Su-Eun Han, Ga-Yong Shim, II-Hwan Cho, Sei-Kwang Hahn